



REVIEW

Improved Cardiovascular Disease Outcomes in Older Adults [version 1; referees: 3 approved]

Daniel E. Forman¹, Karen Alexander², Ralph G. Brindis³, Anne B. Curtis⁴,
Mathew Maurer⁵, Michael W. Rich⁶, Laurence Sperling⁷, Nanette K. Wenger⁸

¹Geriatric Cardiology Section, University of Pittsburgh Medical Center, Geriatric Research, Education, and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA

²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

³Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, USA

⁴Department of Medicine, University at Buffalo, Buffalo, New York, USA

⁵Department of Medicine, Columbia University Medical Center, New York, USA

⁶Washington University School of Medicine, St Louis, MO, USA

⁷Emory University School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA

⁸Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, USA

v1 First published: 28 Jan 2016, 5(F1000 Faculty Rev):112 (doi: 10.12688/f1000research.7088.1)

Latest published: 28 Jan 2016, 5(F1000 Faculty Rev):112 (doi: 10.12688/f1000research.7088.1)

Abstract

Longevity is increasing and the population of older adults is growing. The biology of aging is conducive to cardiovascular disease (CVD), such that prevalence of coronary artery disease, heart failure, valvular heart disease, arrhythmia and other disorders are increasing as more adults survive into old age. Furthermore, CVD in older adults is distinctive, with management issues predictably complicated by multimorbidity, polypharmacy, frailty and other complexities of care that increase management risks (e.g., bleeding, falls, and rehospitalization) and uncertainty of outcomes. In this review, state-of-the-art advances in heart failure, acute coronary syndromes, transcatheter aortic valve replacement, atrial fibrillation, amyloidosis, and CVD prevention are discussed. Conceptual benefits of treatments are considered in relation to the challenges and ambiguities inherent in their application to older patients.



This article is included in the **F1000 Faculty Reviews** channel.

Open Peer Review

Referee Status:

	Invited Referees		
	1	2	3
version 1 published 28 Jan 2016			

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Joseph Alpert**, University of Arizona USA
- 2 **Brian Olshansky**, University of Iowa USA
- 3 **Michael Gaziano**, Brigham and Women's Hospital, Harvard Medical School USA

Discuss this article

Comments (0)

Corresponding author: Daniel E. Forman (formand@pitt.edu)

How to cite this article: Forman DE, Alexander K, Brindis RG *et al.* **Improved Cardiovascular Disease Outcomes in Older Adults [version 1; referees: 3 approved]** *F1000Research* 2016, 5(F1000 Faculty Rev):112 (doi: [10.12688/f1000research.7088.1](https://doi.org/10.12688/f1000research.7088.1))

Copyright: © 2016 Forman DE *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: Mathew Maurer's institution, Columbia University Medical Center, receives funding for research and serving on advisory boards and DSMBs from Pfizer Inc., Alnylam Pharmaceuticals Inc., ISIS Pharmaceuticals and Prothena Inc.

Competing interests: Dr. Forman: No COI Ralph Brindis: No COI Anne Curtis: • Advisory board: Daiichi Sankyo Pfizer, Inc. Janssen Pharmaceuticals St. Jude Medical • Honoraria: St. Jude Medical Medtronic, Inc. • Consultant: Medtronic, Inc. Michael Rich: No COI Laurence Sperling: No COI Nanette Wenger: No COI

First published: 28 Jan 2016, 5(F1000 Faculty Rev):112 (doi: [10.12688/f1000research.7088.1](https://doi.org/10.12688/f1000research.7088.1))

Introduction

The unprecedented growth of the elderly population throughout the world is evolving as a challenge for clinicians, governments, and health policy guidance. Older adults differ from those typically studied in clinical trials, efficacy and outcomes of care often remain ambiguous for older patients, and growing healthcare cost burdens for older adults are a related concern. In this review, we highlight some key advances associated with improved outcomes that have recently occurred in the management of older adults with cardiovascular disease.

Demographics

The population of older adults is growing rapidly, particularly as longevity is also increasing. In the United States, the population aged 65 and over is projected to be 83.7 million by 2050, almost double the 43.1 million in 2012¹. The numbers of those who are very old (≥ 85 years) is growing the most rapidly. On a global level, the population ≥ 85 years is projected to increase 151% between 2005 and 2030, compared to the increase of only 104% in the population aged ≥ 65 years and only 21% for the population under 65². Similar growth of elderly populations is occurring in both developed and developing countries. Between 2012 and 2030, the percentages of adults older than 65 years are expected to increase 33.2% in Japan, 27.9% in Germany, and 25.5% in Italy³. In China, the world's most populous country of 1.4 billion, the subgroup aged ≥ 65 years is expected to increase by 17.2% by 2030 and 26.8% by 2050, or stated as numbers, 350 million Chinese (a magnitude that is greater than the total US population) will soon be senior adults³.

Distinctive implications of aging

Geriatric features often transform healthcare challenges and are important concerns for clinical decision-making. Whereas cardiovascular management standards are fundamentally oriented to specific cardiac diseases, older adults typically present with multiple disease states occurring concurrently such that presentation and management of the cardiac issues are inherently more complex⁴. In some cases, multimorbid disease states lead to compounding instabilities (e.g. heart failure [HF] and renal failure). In other cases, multimorbidities give rise to new disease states (e.g. HF and preserved ejection fraction [HFpEF] arising from the substrate of metabolic disease and inflammation)⁵. Non-cardiac comorbid conditions also underlie much of the morbidity and rehospitalizations associated with HF, particularly HFpEF⁶. Geriatric syndromes are part of multimorbidity; frailty, sarcopenia, cognitive decline, and other age-related dimensions of health fundamentally compound multimorbidity management complexities of cardiac conditions⁷. These insights highlight the importance of a holistic approach in relation to HF as well as other cardiovascular diseases (CVDs) and call attention to the wide range of idiosyncratic capacities, vulnerabilities, and therapeutic objectives that typically distinguish one older cardiac patient from another. Similarly, typical cardiac medications (e.g. angiotensin-converting enzyme [ACE] inhibitors) must be regarded not only in terms of their evidence-based cardiac benefits but also in respect to the iatrogenesis they more easily (even predictably) provoke among older adults (e.g. syncope and falls) in the context of hypotension, balance or vision impairment, sleep deprivation, alcohol use, and other common conditions in an older patient population⁸.

Heart failure

Therapeutic options for the management of HF in older adults include medications, devices, and behavioral interventions. The PARADIGM-HF trial randomized 8442 patients with symptomatic HF and a left ventricular ejection fraction $\leq 40\%$ to the ACE inhibitor enalapril or to the combination of the angiotensin-receptor blocker valsartan and the neprilysin inhibitor sacubitril⁹. Compared to enalapril, valsartan/sacubitril was associated with significant reductions in cardiovascular death or hospitalization for HF, as well as all-cause mortality, cardiovascular mortality, HF hospitalizations, and HF-related symptoms. Patients ≥ 65 years and those ≥ 75 years derived similar benefits from combination therapy, as did younger patients. Based on these findings, it is anticipated that valsartan/sacubitril will be rapidly incorporated into the management of older and younger patients with HF and reduced ejection fraction (HFrEF).

In contrast to HFrEF, the treatment of patients with HFpEF, the vast majority of whom are elderly, remains problematic. In the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, spironolactone failed to reduce the primary outcome of cardiovascular death, aborted cardiac arrest, or HF hospitalizations¹⁰. Spironolactone reduced HF hospitalizations at the expense of increased rates of hyperkalemia and elevated serum creatinine. Hence, the role of spironolactone in the management of HFpEF remains uncertain.

In the realm of devices, the value of implantable cardioverter-defibrillators (ICDs) in patients ≥ 75 years of age remains controversial, and selection of older patients for ICDs must be individualized¹¹. Mechanical circulatory support (MCS) appears to be associated with improved outcomes in carefully selected older adults with advanced HF, albeit with increased risk of complications compared to younger patients¹². Pre-morbid frailty is a strong predictor of worse outcomes in older adults receiving MCS¹³.

In the domain of behavioral interventions, there is a need for novel approaches that address HF not in isolation, but rather in the context of a complex array of comorbid conditions and heterogeneous personal preferences regarding goals of care in order to optimize patient-centered outcomes¹⁴. In addition, the management of HF in long-term care facilities and at the end-of-life now raises special considerations to maximize quality of life and reduce suffering^{15,16}.

Acute coronary syndrome

Recent developments in antithrombotic therapy as well as better information on frailty and outcomes have benefitted older adults with acute coronary syndrome (ACS). A clinical challenge in older adults presenting with a myocardial infarction (MI) or undergoing percutaneous coronary intervention (PCI) is the indication for multiple antithrombotic agents (e.g. atrial fibrillation [AF] or valvular disease). Triple therapy increases the rate of major bleeding, an outcome already common among older adults. Two recent European registry studies further the understanding of antithrombotic therapy in patients with AF with MI and/or undergoing PCI. Among older adults requiring oral anticoagulation presenting with MI or undergoing PCI, clopidogrel added to oral anticoagulant therapy was as effective as triple therapy (including aspirin) in preventing MI/coronary death, ischemic stroke, and bleeding¹⁷. In another

study, among patients requiring oral anticoagulation undergoing PCI (80% ACS, 65% drug-eluting stent and 30% bare metal stent), use of clopidogrel without aspirin was also associated with less bleeding and no increase in thrombotic events during follow up¹⁸. A supporting secondary analysis from a large AF clinical trial found the oral anticoagulant apixaban had similar beneficial effects on stroke, MI, and major bleeding, with or without aspirin, compared with warfarin¹⁹. Ongoing research is exploring the ability to omit aspirin in the setting of an effective oral anticoagulant. These new and safer antithrombotic strategies will be an important advance for high-risk individuals with coronary artery disease and indications for oral anticoagulation.

Older adults are at high risk of adverse outcomes following MI, but a Medicare linkage analysis from the CRUSADE Registry provides evidence that most mortality occurs early and not in the context of rehospitalization. Contrary to expectations, rehospitalization rate did not rise substantially with age, in part due to competing mortality. Rehospitalizations which did occur were often for non-cardiac diagnoses, underscoring the multimorbidity also present in the older population with a coronary event²⁰. The Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial, which randomized 9326 patients with MI planned for medical management to prasugrel or clopidogrel, added frailty assessment at baseline for patients aged ≥ 65 years²¹. The modified Fried score classified 23.0% of the older adults in this trial as pre-frail (1–2 items) and 4.7% as frail (≥ 3 items). After adjustment, frailty remained independently associated with the composite of cardiovascular death, MI, or stroke: pre-frail vs. not-frail, hazard ratio (HR): 1.33; 95% confidence interval (CI): 1.15–1.54; $p < 0.001$; frail vs. not-frail, HR: 1.52; 95% CI: 1.18–1.98; $p = 0.002$. Frailty among registry populations is higher than in clinical trials, so care delivery models should add early targeted follow up in older adults after MI, particularly for those with multimorbidity or frailty. Future studies will benefit from collecting frailty data to allow comparative effectiveness and outcomes comparisons across older MI or PCI populations.

Transcatheter aortic valve replacement

Transcatheter aortic valve replacement (TAVR) represents an innovative interventional technology that provides a non-surgical alternative for the management of severe aortic stenosis (AS) that has particular relevance for the elderly and the very elderly populations. The prevalence of AS in the US is estimated to be greater than 4–5% of those over 75 years of age. Approximately 50% of all US patients and over 75% of those over 80 years of age having clinical indications for surgical aortic valve replacement (AVR) are not being surgically treated due to either the lack of referral by clinicians or patient/family refusal. The use of TAVR has been projected to make substantial inroads in this underserved population, particularly those who are very elderly or deemed at high surgical risk.

The key randomized clinical trials (RCTs) PARTNER A & B (utilizing Edwards' Sapien balloon expandable AVR) along with the CoreValve (Medtronic's self-expanding percutaneous AVR) study of high-risk patients conclusively demonstrated improved long-term patient survival employing TAVR compared to sAVR (standard

surgical AVR) with acceptable stroke and bleeding rates for patients felt either surgically inoperable or at very high surgical risk. The median age of TAVR implantation in these study cohorts was approximately 84 years^{22,23}.

TAVR had been available for clinical use in over 31 countries prior to United States FDA approval in 2011. To help ensure a rational diffusion of TAVR's innovative technology partnerships between the Food and Drug Administration (FDA), the Center for Medicare and Medical Services (CMS) along with cardiovascular professional societies led by the American College of Cardiology (ACC) and the Society for Thoracic Surgery (STS) collaborated in the creation of critical Post Approval Studies, CMS Coverage Determination Criteria, a multi-societal competency document for institutional and professional utilization of TAVR technology accompanied by an expert consensus document and clinical practice guidelines for TAVR clinical use. STS and ACC have created the STS/ACC transcatheter valve therapy (TVT) Registry where all commercial TAVR implants are required to be enrolled by hospitals to satisfy CMS coverage and payment requirements^{24–27}. As of spring 2015, over 30,000 TAVR patients from approximately 350 institutions have been entered into the TVT Registry.

The TVT Registry data has been instrumental in assuring quality of care along with providing the infrastructure for performing Post Approval Studies, Investigational Device Exemption Studies, and Post Market Surveillance^{28,29}. The Registry allowed earlier FDA approval than would be possible through previous RCT mechanisms for "Valve-in-Valve" TAVR use and also for alternative access use in high-risk and surgically inoperable patients. The TVT Registry demonstrated 7.0% 30-day mortality, and 23.7% 1-year mortality with a stroke rate of 4.1%³⁰.

Of great importance for assessing clinical decision-making for elderly patients with AS, the TVT Registry is collecting both baseline and longitudinal data on frailty and activity limitation assessments through 5-meter walk tests and the Kansas City Cardiomyopathy Questionnaire (KCCQ). In addition, the TVT Registry is creating a risk-adjusted mortality model that will hopefully soon be transformed into a predictive outcome tool to help clinicians, patients, and families make informed decisions in the management of elderly and very elderly patients with AS.

Atrial fibrillation

The median age of patients with AF is 75 years, with a prevalence of about 9% in the elderly³¹. Stroke stands out as one of the greatest risks attributable to this arrhythmia. The 2014 American Heart Association/ACC/Heart Rhythm Society (AHA/ACC/HRS) guideline³² recommends using the CHA₂DS₂-VASc (Congestive HF [CHF], Hypertension, Age ≥ 75 years, Diabetes, Stroke/Transient ischemic attack [TIA], Vascular disease, Age 65–74, Sex category [female]) score to assess stroke risk. The guideline recommends oral anticoagulant therapy for AF patients with a CHA₂DS₂-VASc > 2 using warfarin or one of the new oral anticoagulants (NOACs) dabigatran, rivaroxaban, or apixaban. Edoxaban is another NOAC that was approved for use after the guideline was published, but it has efficacy that is comparable to those approved earlier.

As age >75 years leads to a minimum CHA₂DS₂-VASc score of 2, many emphasize the value of anticoagulation for most elderly patients with AF and decry the underuse of such vital therapy. Nonetheless, this still remains an issue of debate amidst age-related intricacies of care, i.e. intrinsic bleeding risks are often compounded by frailty, multimorbidity, polypharmacy, falls, and other management complexities.

There have been several studies to estimate the risk/benefit ratio of treating elderly AF patients with oral anticoagulation, including the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study³³, which randomized individuals aged ≥75 years of age to aspirin or warfarin based on physician discretion. Stroke/systemic embolism (SE) occurred at a rate of 1.8%/year in warfarin-treated patients versus 3.8%/year in the aspirin group (HR 0.48; 95% CI, 0.28–0.80), with no difference in the rates of major hemorrhage (1.9 vs. 2.2%, respectively). The risk for bleeding with warfarin therapy in patients >80 years of age has been estimated to range from 1.63% to 13.1% per year^{34,35}.

The NOACs have generated much excitement in the field of AF management, as they enable relatively simplified treatment compared to warfarin (e.g. reduced need for blood testing and no dietary restrictions). NOACs that include both direct thrombin inhibitors (dabigatran) and factor X inhibitors (rivaroxaban, apixaban, and edoxaban) are now available as alternatives to warfarin. All have been shown to be non-inferior to warfarin with respect to stroke and SE, with comparable rates of bleeding^{36–39}. The mean age of patients in these studies was approximately 70 years, with about one-third of the patients being over 75 years.

A recent meta-analysis of the efficacy and harm of the NOACs for prevention of stroke in AF and secondary prevention of thromboembolism found that the efficacy of each of the NOACs was equal or superior to warfarin in elderly patients⁴⁰. Dabigatran was associated with a higher risk of gastrointestinal bleeding and a lower risk of intracranial bleeding. A significantly lower risk of major bleeding compared to warfarin was found for apixaban (odds ratio 0.63, 95% CI 0.51–0.77) and edoxaban 60 mg (0.81, 0.67–0.98) and 30 mg (0.46, 0.38–0.57), while rivaroxaban showed similar risks.

Amyloidosis

Cardiac amyloid has traditionally been considered a rare cardiovascular condition. However, emerging data demonstrate that transthyretin cardiac amyloidosis (ATTR), formerly known as senile cardiac amyloidosis, caused by misfolded monomers or oligomers of the protein transthyretin (TTR), is a common cause of HFpEF. Indeed recent autopsy studies in HFpEF subjects (mean age 76 years) showed 21% had amyloid deposits and the prevalence was greater in those ≥75 years (32%) vs. <75 years (8%). Furthermore, only 20% of the HFpEF patients with amyloid at autopsy had received a pre-morbid diagnosis⁴¹.

Bone isotopes, commonly used in bone scans, have a high sensitivity and specificity (>90%) for identifying TTR cardiac amyloid due to either wild-type TTR or a mutant allele^{42,43}. While over 20 mutations can cause TTR cardiac amyloidosis, the Val122Ile mutation (substitution of isoleucine for valine at position 122) is

the most common in the United States with a particularly high frequency (prevalence of 3.4% to 3.9%) in African-Americans⁴⁴. The Thr60Ala mutation (substitution of alanine for threonine at position 60) is also notably common in individuals of Irish descent and is referred to as the Appalachian mutation. These genetic conditions have an age-dependent penetrance, with males over the age of 60 years being most commonly affected.

Historically, cardiac amyloid was difficult to diagnose because it can masquerade as other cardiovascular disorders⁴⁵ and usually required endomyocardial biopsy. The diagnosis has become easier with the discovery that bone isotopes have a very high sensitivity and specificity for distinguishing ATTR cardiac amyloid (both mutant and wild-type) from light chain (AL) cardiac amyloid⁴⁶ and other types of cardiomyopathy that mimic amyloid (e.g. hypertrophic cardiomyopathy). Differentiating TTR from AL cardiac amyloid has important prognostic, management, counseling, and therapeutic implications. These nuclear medicine techniques have the potential to dramatically alter the outcomes of patients with ATTR cardiac amyloidosis, particularly because new therapeutic options are looming.

Emerging therapeutic strategies to treat ATTR amyloid are focused on small molecules to stabilize the transthyretin tetramer and agents to silence TTR production. Phase II clinical trial data⁴⁷ suggest that tafamidis was generally well tolerated and stabilized TTR, leading to a phase III clinical trial that has completed enrollment. TTR silencers using either small interfering RNA (siRNA) or oligonucleotides specific for silencing TTR production have shown remarkable ability to lower TTR to >80% of normal levels in subjects with TTR cardiac amyloidosis. Collectively, such data remind us that TTR cardiac amyloid is certainly not rare and hopefully not unmodifiable.

Preventive care

Recent guidelines for cardiovascular prevention importantly emphasize that older adults are at highest risk for atherosclerotic cardiovascular events. Paradoxically, however, strategies focused on cardiovascular prevention are often underutilized in this subpopulation⁴⁸. As the elderly also have the greatest burden of comorbidities, polypharmacy, and potential for medication-related side effects, the need for comprehensive and collaborative clinician-patient management is imperative⁴⁹.

Potential overtreatment of hypertension, in addition to inadequate control, may cause adverse outcomes in the elderly, who are more likely to have target organ damage. Considerable debate has arisen from the guideline recommendations made by the panel members appointed to JNC 8 (Eighth Joint National Committee) that blood pressure should be reduced to less than 150/90 mm Hg in adults aged 60 years and older without diabetes or chronic kidney disease⁵⁰. In support of the ACC/AHA 2011 Expert Consensus document on hypertension in the elderly⁵¹ that recommended blood pressure be reduced to less than 140/90 in adults aged 60–79 (and a systolic pressure of 140–145 if tolerated in adults aged 80 and older) are data from REGARDS (REasons for Geographic and Racial Differences in Stroke), which reported that optimal blood pressure for elderly patients on antihypertensive therapy for the reduction of cardiovascular events and all-cause mortality was less than 140/90 mm Hg⁵².

Several recommended caveats for the care of older adults are highlighted by the ACC/AHA 2013 guidelines for the treatment of blood cholesterol, including the use of moderate-intensity statin therapy in adults >75 years of age with established atherosclerotic CVD (ASCVD). The ASCVD pooled cohort risk estimator does not provide for risk assessment in patients >79 years of age⁵³. When initiating statin therapy, the risk of transitioning to diabetes should be discussed, although this risk is small in relation to the potential benefits of statin medications. Importantly, there is no definitive evidence that statins lead to cognitive decline. The available data on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy in those of advanced age is promising, as low-density lipoprotein (LDL)-C is potently reduced with a side effect profile similar to that of placebo⁵⁴.

Lifestyle approaches remain the cornerstone for cardiovascular prevention in the elderly. Among persons aged 55 to 80 (mean age 67) at increased cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced the incidence of major cardiovascular events by 30%⁵⁵. Emphasizing a goal of living longer and better, a Mediterranean lifestyle including dietary pattern, moderate alcohol intake, regular physical activity, and not smoking was associated with a 60% reduction in all-cause mortality in elderly Europeans aged 70–90⁵⁶.

The value of geriatric measures in patient-centered decision-making for clinical cardiovascular problems

In general, medications, procedures, and other components of cardiovascular care are more likely to entail trade-offs at elderly age. Polypharmacy, pain, fatigue, confusion, dysgeusia, excessive time for recovery, and other sequelae may detract from (and sometimes even supersede) intended therapeutic benefits^{57,58}. Whereas life prolongation is the overriding goal of therapy in the young, for many seniors issues of independence, quality of life, and functional capacity are often more important, and this may determine therapeutic choices that contrast with those of younger populations. This broader spectrum of clinical objectives and the high susceptibility to iatrogenesis are driving rationales for a growing emphasis on principles of shared decision-making between older patients and their clinicians^{57,58}.

Other age-related issues that commonly affect caregiving of older cardiac patients include frailty, altered body composition (diminished

lean body mass and increased interstitial fat), and changes in cognition. Frailty is often assessed as a constellation of phenotypic changes that relate to a state of increased vulnerability, i.e. slowing, weakening, weight loss, exhaustion, and reduced activity⁵⁹. Patients with three or more of these measures are considered frail and are generally at increased risk for disease but also for poor tolerance of therapy. Frailty therefore fundamentally factors into therapeutic decisions and management strategies. Sarcopenia or reduced lean body mass is a subpart of frailty and directly detracts from physical capacity and vital resiliency to recover⁶⁰. Diminished cognition, particularly executive function, is similarly insidious and detrimental, and complicating with regard to decision-making and adherence, and even in respect to the quality of life benefits that are achievable by therapy⁶¹.

Competing interests

Dr. Forman: No COI

Ralph Brindis: No COI

Anne Curtis:

- Advisory board:
Daiichi Sankyo
Pfizer, Inc.
Janssen Pharmaceuticals
St. Jude Medical
- Honoraria:
St. Jude Medical
Medtronic, Inc.
- Consultant:
Medtronic, Inc.

Michael Rich: No COI

Laurence Sperling: No COI

Nanette Wenger: No COI

Grant information

Mathew Maurer's institution, Columbia University Medical Center, receives funding for research and serving on advisory boards and DSMBs from Pfizer Inc., Alnylam Pharmaceuticals Inc., ISIS Pharmaceuticals and Prothena Inc.

References

1. Ortman JM, Velkoff VA, Hogan H: **An Aging Nation: The older population in the United States**. 2014.
[Reference Source](#)
2. **National Institute of Aging**. 2015.
[Reference Source](#)
3. U.S. Census Bureau. **International Data Base**. 2009.
[Reference Source](#)
4. Bell SP, Orr NM, Dodson JA, *et al.*: **What to Expect From the Evolving Field of Geriatric Cardiology**. *J Am Coll Cardiol*. 2015; **66**(11): 1286–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Paulus WJ, Tschöpe C: **A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation**. *J Am Coll Cardiol*. 2013; **62**(4): 263–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Mentz RJ, Kelly JP, von Lueder TG, *et al.*: **Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction**. *J Am Coll Cardiol*. 2014; **64**(21): 2281–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Chaudhry SI, Wang Y, Gill TM, *et al.*: **Geriatric conditions and subsequent mortality in older patients with heart failure**. *J Am Coll Cardiol*. 2010; **55**(4): 309–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Chang VC, Do MT: **Risk factors for falls among seniors: implications of gender**. *Am J Epidemiol*. 2015; **181**(7): 521–31.
[PubMed Abstract](#) | [Publisher Full Text](#)



9. **F** McMurray JJ, Packer M, Desai AS, *et al.*: **Angiotensin-neprilysin inhibition versus enalapril in heart failure.** *N Engl J Med.* 2014; 371(11): 993–1004. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
10. **F** Pitt B, Pfeffer MA, Assmann SF, *et al.*: **Spironolactone for heart failure with preserved ejection fraction.** *N Engl J Med.* 2014; 370(15): 1383–92. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
11. Barra S, Providência R, Paiva L, *et al.*: **Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations.** *Europace.* 2015; 17(2): 174–86. [PubMed Abstract](#) | [Publisher Full Text](#)
12. **F** Rosenbaum AN, John R, Liao KK, *et al.*: **Survival in elderly patients supported with continuous flow left ventricular assist device as bridge to transplantation or destination therapy.** *J Card Fail.* 2014; 20(3): 161–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. Flint KM, Matlock DD, Lindenfeld J, *et al.*: **Frailty and the selection of patients for destination therapy left ventricular assist device.** *Circ Heart Fail.* 2012; 5(2): 286–93. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Murad K, Kitzman DW: **Frailty and he selection of patients for destination therapy for left ventricular assist device.** *Circ Hrt Fail.* 2012; 5: 246–93.
15. Jurgens CY, Goodlin S, Dolansky M, *et al.*: **Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America.** *J Card Fail.* 2015; 21(4): 263–99. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Whellan DJ, Goodlin SJ, Dickinson MG, *et al.*: **End-of-life care in patients with heart failure.** *J Card Fail.* 2014; 20(2): 121–34. [PubMed Abstract](#) | [Publisher Full Text](#)
17. **F** Lamberts M, Gislason GH, Olesen JB, *et al.*: **Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.** *J Am Coll Cardiol.* 2013; 62(11): 981–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
18. **F** Dewilde WJ, Oirbans T, Verheugt FW, *et al.*: **Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.** *Lancet.* 2013; 381(9872): 1107–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. **F** Alexander JH, Lopes RD, Thomas L, *et al.*: **Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.** *Eur Heart J.* 2014; 35(4): 224–32. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
20. Lopes RD, Gharacholou SM, Holmes DN, *et al.*: **Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI.** *Am J Med.* 2015; 128(6): 582–90. [PubMed Abstract](#) | [Publisher Full Text](#)
21. White HD, Westerhout CM, Alexander KP, *et al.*: **Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet inhibition to cLarify the Optimal strateGy to medicalIY manage Acute Coronary Syndromes (TRILOGY ACS) trial.** *EEur Heart J Acute Cardiovasc Care.* 2015; pii: 2048872615581502. [PubMed Abstract](#) | [Publisher Full Text](#)
22. **F** Smith CR, Leon MB, Mack MJ, *et al.*: **Transcatheter versus surgical aortic-valve replacement in high-risk patients.** *N Engl J Med.* 2011; 364(23): 2187–98. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. Adams DH, Popma JJ, Reardon MJ: **Transcatheter aortic-valve replacement with a self-expanding prosthesis.** *N Engl J Med.* 2014; 371(10): 967–8. [PubMed Abstract](#) | [Publisher Full Text](#)
24. CMS: **Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430N).** 2015. [Reference Source](#)
25. **F** Mack MJ, Holmes DR Jr: **Rational dispersion for the introduction of transcatheter valve therapy.** *JAMA.* 2011; 306(19): 2149–50. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
26. **F** Holmes DR Jr, Mack MJ; Writing Committee: **Transcatheter valve therapy: a professional society overview from the American College of Cardiology Foundation and the Society of Thoracic Surgeons.** *Ann Thorac Surg.* 2011; 92(1): 380–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Holmes DR Jr, Mack MJ, Kaul S, *et al.*: **2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement.** *J Am Coll Cardiol.* 2012; 59(13): 1200–54. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Carroll JD, Edwards FH, Marinac-Dabic D, *et al.*: **The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies.** *J Am Coll Cardiol.* 2013; 62(11): 1026–34. [PubMed Abstract](#) | [Publisher Full Text](#)
29. Mack MJ, Brennan JM, Brindis R, *et al.*: **Outcomes following transcatheter aortic valve replacement in the United States.** *JAMA.* 2013; 310(19): 2069–77. [PubMed Abstract](#) | [Publisher Full Text](#)
30. **F** Holmes DR Jr, Brennan JM, Rumsfeld JS, *et al.*: **Clinical outcomes at 1 year following transcatheter aortic valve replacement.** *JAMA.* 2015; 313(10): 1019–28. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. Rosamond W, Flegal K, Furie K, *et al.*: **Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.** *Circulation.* 2008; 117(4): e25–146. [PubMed Abstract](#) | [Publisher Full Text](#)
32. January CT, Wann LS, Alpert JS, *et al.*: **2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.** *Circulation.* 2014; 130(23): 2071–104. [PubMed Abstract](#) | [Publisher Full Text](#)
33. **F** Mant J, Hobbs FD, Fletcher K, *et al.*: **Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.** *Lancet.* 2007; 370(9586): 493–503. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
34. **F** Poli D, Antonucci E, Testa S, *et al.*: **Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.** *Circulation.* 2011; 124(7): 824–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. **F** Hylek EM, Evans-Molina C, Shea C, *et al.*: **Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.** *Circulation.* 2007; 115(21): 2689–96. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Connolly SJ, Ezekowitz MD, Yusuf S, *et al.*: **Dabigatran versus warfarin in patients with atrial fibrillation.** *N Engl J Med.* 2009; 361(12): 1139–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. **F** Patel MR, Mahaffey KW, Garg J, *et al.*: **Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.** *N Engl J Med.* 2011; 365(10): 883–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. **F** Granger CB, Alexander JH, McMurray JJ, *et al.*: **Apixaban versus warfarin in patients with atrial fibrillation.** *N Engl J Med.* 2011; 365(11): 981–92. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. **F** Giugliano RP, Ruff CT, Braunwald E, *et al.*: **Edoxaban versus warfarin in patients with atrial fibrillation.** *N Engl J Med.* 2013; 369(22): 2093–104. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. **F** Sharma M, Cornelius VR, Patel JP, *et al.*: **Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.** *Circulation.* 2015; 132(3): 194–204. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Mohammed SF, Mirzoyev SA, Edwards WD, *et al.*: **Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.** *JACC Heart Fail.* 2014; 2(2): 113–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. González-López E, Gallego-Delgado M, Guzzo-Merello G, *et al.*: **Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.** *Eur Heart J.* 2015; 36(38): 2585–94. [PubMed Abstract](#) | [Publisher Full Text](#)
43. Maurer MS: **Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology.** *Am J Med.* 2015; 128(12): 1275–80. [PubMed Abstract](#) | [Publisher Full Text](#)
44. **F** Quarta CC, Buxbaum JN, Shah AM, *et al.*: **The amyloidogenic V122I transthyretin variant in elderly black Americans.** *N Engl J Med.* 2015; 372(1): 21–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. Rapezzi C, Lorenzini M, Longhi S, *et al.*: **Cardiac amyloidosis: the great pretender.** *Heart Fail Rev.* 2015; 20(2): 117–24. [PubMed Abstract](#) | [Publisher Full Text](#)
46. Bokhari S, Castaño A, Pozniakoff T, *et al.*: **^{99m}Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.** *Circ Cardiovasc Imaging.* 2013; 6(2): 195–201. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Maurer MS, Grogan DR, Judge DP, *et al.*: **Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.** *Circ Heart Fail.* 2015; 8(3): 519–26. [PubMed Abstract](#) | [Publisher Full Text](#)
48. Wilmot KA, Khan A, Krishnan S, *et al.*: **Statins in the elderly: a patient-focused approach.** *Clin Cardiol.* 2015; 38(1): 56–61. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Martin SS, Sperling LS, Blaha MJ, *et al.*: **Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.** *J Am Coll Cardiol.* 2015; 65(13): 1361–8. [PubMed Abstract](#) | [Publisher Full Text](#)

50. James PA, Oparil S, Carter BL, *et al.*: **2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).** *JAMA*. 2014; **311**(5): 507–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Aronow WS, Fleg JL, Pepine CJ, *et al.*: **ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.** *J Am Coll Cardiol*. 2011; **57**(20): 2037–114.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. **F** Banach M, Bromfield S, Howard G, *et al.*: **Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication.** *Int J Cardiol*. 2014; **176**(1): 219–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. Stone NJ, Robinson JG, Lichtenstein AH, *et al.*: **2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Circulation*. 2014; **129**(25 Suppl 2): S1–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Koren M, Rosenson R, Khan B, *et al.*: **Ldl cholesterol reduction in elderly patients with the pcsk9 monoclonal antibody evolocumab (amg 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies.** *J Am Coll Cardiol*. 2015; **65**(10): A1366.
[Publisher Full Text](#)
55. **F** Estruch R, Ros E, Salas-Salvadó J, *et al.*: **Primary prevention of cardiovascular disease with a Mediterranean diet.** *N Engl J Med*. 2013; **368**(14): 1279–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
56. **F** Knoops KT, Kim TB, de Groot LC, *et al.*: **Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project.** *JAMA*. 2004; **292**(12): 1433–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
57. Lorgunpai SJ, Grammas M, Lee DS, *et al.*: **Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition.** *PLoS One*. 2014; **9**(2): e89447.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. **F** Case SM, O'Leary J, Kim N, *et al.*: **Older Adults' Recognition of Trade-Offs in Healthcare Decision-Making.** *J Am Geriatr Soc*. 2015; **63**(8): 1658–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. Afilalo J, Alexander KP, Mack MJ, *et al.*: **Frailty assessment in the cardiovascular care of older adults.** *J Am Coll Cardiol*. 2014; **63**(8): 747–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. **F** Milte R, Crotty M: **Musculoskeletal health, frailty and functional decline.** *Best Pract Res Clin Rheumatol*. 2014; **28**(3): 395–410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
61. **F** Cannon JA, McMurray JJ, Quinn TJ, *et al.*: **'Hearts and minds': association, causation and implication of cognitive impairment in heart failure.** *Alzheimers Res Ther*. 2015; **7**(1): 22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 Michael Gaziano**, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA
Competing Interests: No competing interests were disclosed.
- 2 Brian Olshansky**, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
Competing Interests: No competing interests were disclosed.
- 3 Joseph Alpert**, Department of Medicine, University of Arizona, Tucson, Arizona, USA
Competing Interests: No competing interests were disclosed.